EGFR and hepatocellular carcinoma: It is noteworthy that while mTOR inhibitors, as well as other therapeutics targeting the EGFR/PI3K/AKT/mTOR pathway, have shown some promise in preclinical studies, their efficacy in patients with advanced HCC remains uncertain.